Borgeson Blake sold $155K of RXRX

Borgeson Blake sold 40,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.88 ($0.16M total) on 2026-11-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borgeson Blake
Published Nov 4, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RXRX
Bearish
high confidence
Mentioned
$RXRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new information for traders.

02

Market read

Small insider sale may cause slight short‑term price pressure but is unlikely to move the broader market.

03

What to watch

The director retains a large stake, suggesting continued confidence.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$RXRXBearishHigh confidence
Context

Director Borgeson Blake sold 40,000 shares for $155,200 via a 10b5‑1 plan, reducing his holdings to 6,068,287 shares.

Expected impact

likely modest pressure as the market prices in the insider sale

Evidence & confidence

Form 4 filing is a primary source; the sale amount is small but could be interpreted as a lack of confidence.

Market effects

Minimal impact on the biotech sector.

None

Low

Counterpoint

The sale may be routine under a pre‑arranged plan and not indicative of future performance.

Key entities

  • Recursion Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker RXRX.

  • Borgeson Blake

    Director of Recursion Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.